InvestSMART

Pacific Edge Limited (ASX: PEB) - Announcements

Current share price for PEB : $0.185 0.005 (2.63%)+

ASX company news and announcements for Pacific Edge Limited (PEB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pacific Edge Limited (PEB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pacific Edge Limited (PEB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pacific Edge Limited (PEB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$230 Pacific Edge 2022 Annual Shareholders Meeting - Results 29 Jul 2022 7:43AM $0.660 $0.185 fallen by 71.97%
$230 Pacific Edge 2022 Annual Shareholders Meeting 28 Jul 2022 1:08PM $0.660 $0.185 fallen by 71.97%
$230 Pacific Edge Appoints Chief Operating Officer 28 Jul 2022 7:33AM $0.660 $0.185 fallen by 71.97%
$230 Southern District Health Region Adopts Cxbladder Tests 21 Jul 2022 7:30AM $0.640 $0.185 fallen by 71.09%
$230 Pacific Edge Investor Update - Q1 FY23 Test Volumes Rise 32% 20 Jul 2022 7:36AM $0.640 $0.185 fallen by 71.09%
$230 Notice of Annual General Meeting/Proxy Form 22 Jun 2022 12:46PM $0.615 $0.185 fallen by 69.92%
$230 Annual Report to shareholders 22 Jun 2022 7:52AM $0.615 $0.185 fallen by 69.92%
$230 Kaiser Permanente agrees to Cxbladder EMR Integration 1 Jun 2022 2:21PM $0.620 $0.185 fallen by 70.16%
$230 Pacific Edge LTD FY22 Result 26 May 2022 9:23AM $0.685 $0.185 fallen by 72.99%
$230 PEB FY22 Result - NZX Announcement Template 26 May 2022 9:15AM $0.685 $0.185 fallen by 72.99%
$230 Director Nomination Closing Date 23 May 2022 1:17PM $0.755 $0.185 fallen by 75.50%
$230 Clinical Study Advancing Cxbladder as standard of care 10 May 2022 8:32AM $0.775 $0.185 fallen by 76.13%
$230 Pacific Edge Full Year Result to be Announced 26 May 2022 3 May 2022 10:17AM $0.820 $0.185 fallen by 77.44%
$230 D&O Disclosure - NZX - D Darling 28 Apr 2022 12:47PM $0.800 $0.185 fallen by 76.88%
$230 Capital Change Notice - NZX 26 Apr 2022 1:00PM $0.810 $0.185 fallen by 77.16%
$230 Application for quotation of securities - PEB 26 Apr 2022 12:56PM $0.810 $0.185 fallen by 77.16%
$230 PEB Investor Update - March 2022 30 Mar 2022 10:15AM $0.860 $0.185 fallen by 78.49%
$230 Pacific Edge Appoints Tony Barclay to its Board 17 Mar 2022 7:31AM $0.770 $0.185 fallen by 75.97%
$230 Application for quotation of securities - PEB 3 Mar 2022 12:21PM $0.885 $0.185 fallen by 79.10%
$230 Application for quotation of securities - PEB 3 Mar 2022 12:10PM $0.885 $0.185 fallen by 79.10%
$230 Capital Change Notice - NZX 3 Mar 2022 11:54AM $0.885 $0.185 fallen by 79.10%
$230 Notification regarding unquoted securities - PEB 18 Feb 2022 12:22PM $0.985 $0.185 fallen by 81.22%
$230 D&O Disclosure - NZX - Peter Meintjes 18 Feb 2022 11:35AM $0.985 $0.185 fallen by 81.22%
$230 Capital Change Notice - NZX 18 Feb 2022 11:31AM $0.985 $0.185 fallen by 81.22%
$230 Dr Peter Meintjes commences as Pacific Edge Chief Executive 19 Jan 2022 7:30AM $1.175 $0.185 fallen by 84.26%

201 - 225 of 267 results

Page 9 of 11

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.